BWAY Brainsway
- 5.380
- -0.020-0.37%
- 5.400
- +0.020+0.37%
Brainsway News
Brainsway Price Target Raised to $11.00/Share From $10.00 by Oppenheimer
Brainsway Price Target Raised to $11.00/Share From $10.00 by Oppenheimer
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Baird raise
HC Wainwright & Co. : Maintaining the BrainsWay (BWAY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $15.00.
HC Wainwright & Co. : Maintaining the BrainsWay (BWAY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $15.00.
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $15
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target from $13 to $15.
Buy Rating Affirmed for Brainsway Following Strong Financial Performance and Strategic Advancements
BrainsWay Announces Strong Q1 2024 Financial Growth
BrainsWay Reiterates FY24 Revenue Guidance Of $37M-$40M, Est $37.779M
This would represent growth of 16% to 26% over full-year 2023 revenue. In addition, it continues to anticipate that profitability momentum and positive cash generation will continue throughout 2024.
BrainsWay Q1 Sales $9.095M Beat $8.720M Estimate
BrainsWay (NASDAQ:BWAY) reported quarterly sales of $9.095 million which beat the analyst consensus estimate of $8.720 million by 4.30 percent. This is a 37.28 percent increase over sales of $6.625 m
6-K: Report of foreign private issuer (related to financial reporting)
BrainsWay Sees FY24 Rev $37M-$40M >BWAY.TA.TV
BrainsWay Sees FY24 Rev $37M-$40M >BWAY.TA.TV
BrainsWay 1Q Rev $9.1M >BWAY.TA.TV
BrainsWay 1Q Rev $9.1M >BWAY.TA.TV
BrainsWay 1Q EPS 0c >BWAY.TA.TV
BrainsWay 1Q EPS 0c >BWAY.TA.TV
BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
BrainsWay Expands Deep TMS Treatment Access in Israel
BrainsWay's Deep TMS Shows Promise for Parkinson's
BrainsWay Announces Publication Of Results In Late-Life Depression Post-Marketing Analysis In Journal of Clinical Medicine
BrainsWay Announces Publication Of Results In Late-Life Depression Post-Marketing Analysis In Journal of Clinical Medicine
All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy
BrainsWay's Existing Partner, Katie's Way Plus Has Ordered An Additional 18 Deep Transcranial Magnetic Stimulation (Deep TMS) Systems. Katie's Way Plus Will Now Grow To Approximately 40 Deep TMS Systems
BrainsWay's Existing Partner, Katie's Way Plus Has Ordered An Additional 18 Deep Transcranial Magnetic Stimulation (Deep TMS) Systems. Katie's Way Plus Will Now Grow To Approximately 40 Deep TMS Syste
BrainsWay Broadens Partnership With Katie's Way Plus Through Order of an Additional 18 Deep TMS Systems
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced today that its significant existing partner, Katie's Way Plus, which provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families, has ordered an additional 18 Deep Transcranial Magnetic Stimulation (Deep TMS) systems.
Brainsway Is Maintained at Buy by HC Wainwright & Co.
Brainsway Is Maintained at Buy by HC Wainwright & Co.
Analysis
Price Target
No Data
